Research Roundup

Debbie Rigby rounds up the latest in research news Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk A systematic review and meta-analysis was performed to investigate the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk. A 1- or 3-month abbreviated DAPT

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Feminised workforce opting for part-time roles
Next 'Strong supporter’ of pharmacy named NSW Health Minister